Business
Laboratorios Farmaceuticos Rovi S A : First half 2025 results press release
Laboratorios Farmaceuticos Rovi S A : First half 2025 results press
About this update from Laboratorios Farmaceuticos Rovi, S.a.
[{"type":"text","content":"\n \n Español\n \n \n 0x5a1307.jpg\n \n Operating revenue in the first half of 2025 was 314.6 million euros, a 4% decrease on the first half of 2024, mainly due to the performance of the contract development and manufacturing business (\"CDMO\"). However, sales of the specialty pharmaceutical business increased 13% to 237.4 million euros in\n \n \n the first half of 2025.\n \n \n On 9 July 2025, the Technological Development and Innovation Centre (CDTI) published the final decision confirming the award of aid of 36.3 million euros for ROVI's LAISOLID project. This aid covers the period running from January 2023 to August 2026. In the third quarter of 2025, the Company plans to book the revenue relating to the expenses incurred from January 2023 to September 2025 and collect the entire amount awarded, once the administrative procedures required by the awarding body have been completed.\n \n \n Okedi® (Risperidone ISM®) continued its strong growth, reaching total sales of 26.9 million euros in the first half of 2025. This represents a 115% increase on the first half of 2024 and a 14% rise compared to the first quarter of 2025.\n \n \n Sales of the heparin franchise (low-molecular-weight heparins (LMWH) and other heparins) increased by 12% to 135.2 million euros in the first half of 2025, mostly due to an increase in orders from partners during the first half of the year. Enoxaparin was the main contributor to the growth of the division, with sales rising 14% to 79.8 million euros due to stronger international sales in the first six months of the year. In addition, bemiparin sales also increased by 9% to 51.5 million euros in the first half of 2025 compared to the first half of 2024. This rise was driven by Bemiparin international sales which increased by 38% in the period.\n \n \n Good performance of Neparvis®, sales of which increased by 11% in the first half of 2025 compared to the first half of 2024, rising to 27.7 million euros.\n \n \n Gross margin was 62.4% in the first half of 2025, an increase of 3.0 percentage points on the first half of 2024. This increase was mainly due to: (i) the increased contribution of Okedi® sales, which added high margins; (ii) the decrease in LMWH raw material prices, which had a positive impact on gross margin; and (iii) the residual contribution to the CDMO business of revenue related to the ...